logo-loader

RegMed Competitive and Market Intelligence 4/3/12, stocks are wavering in narrow range, ATHX rises and falls while FCSC jumps 114%

Last updated: 14:50 03 Apr 2012 BST, First published: 18:50 03 Apr 2012 BST

no_picture_pai

The 6 W’s: Who, what, where, when, why and what of it …

 

Today’s Gospel:  I don’t feel a trigger for any action … as RegMed companies need … to hone their message and define their path toward regulatory next steps and appreciation catalysts … Who can be exited by anything other then … goodbye by Thursday …!!  

 

EconRecon: Factory orders rebounded 1.3% in February, according to the Commerce Department. Still, the reading was below the 1.5% gain expected.

 

Mid-Day: The NASDAQ is DOWN -4.48 (-0.14%) to 3,115.22 while the Dow is Down -52.60(-0.4%) to 13,211.89.

 

Mid-Day Market Commentary: Stocks fell … after the government says factory orders rose in February and as investors await minutes from the Fed’s past rate meeting.  Traders are … taking a break as stocks show … a lack of direction over the course of mid-day trading on Tuesday. The major averages have been bouncing back and forth across the unchanged line. The choppy trading on Wall Street comes as some traders are staying on the sidelines … for Fed notes. Meanwhile, traders have largely shrugged off the release of a report from the Commerce Department showing that factory orders rebounded by slightly less than expected in the month of February. Notice … I did NOT say investors … but, traders!!

 

Who is UP … Mid-day: 

  • Athersys (ATHX);
  • Cytomedix (OTC BB: CMXI);
  • Dendreon (DNDN);
  • Fibrocell (OTC BB: FCSC);
  • ImmunoCellular (OTC BB: IMUC);
  • International Stem Cell (OTC BB: ISCO);
  • Neuralstem (Amex: CUR);
  • Pluristem (PSTI);
  • Tengion (TNTN).
  • ThermoGenesis (KOOL)

 

What’s new in the regenerative medicine/stem cell market …  to know today …

ReNeuron (RENE.L) Private Placement:  In an open offer to existing shareholders, to raise up to £9.4M, before expenses. In addition, investors in the private placement are being issued Warrants which could raise up to £8.1M for the Company, before expenses. Completion of the proposed offering is subject to shareholder approval,

Stemline Therapeutics, Inc. Files Registration Statement for Proposed IPO: Stemline Therapeutics, a clinical-stage biopharmaceutical company developing oncology therapeutics that targets both cancer stem cells (CSCs) and tumor bulk, has filed a registration statement with the SEC for a proposed initial public offering of its common stock.  The offering size and the estimated price range of the offering have not yet been determined. Oppenheimer & Co. Inc. and JMP Securities LLC are acting as joint book-running managers for the offering.

Pluristem (PSTI) forms Peripheral Artery Disease Steering Committee: https://finance.yahoo.com/news/pluristem-forms-peripheral-artery-disease-110000078.html . A Team of Internationally Renowned Physicians Will Collaborate on Advancing PLX Cell Therapies for Millions of People Suffering From the Chronic Disease

DRI Study Shows Stem Cells Can Replace Anti-Rejection Drug for Transplants: https://med.miami.edu/news/dri-study-shows-stem-cells-can-replace-anti-rejection-drug-for-transplants? . New findings from a transplant study led by scientists from the Diabetes Research Institute at theMillerSchool and a DRI Federation center atXiamenUniversity inChina showed that mesenchymal stem cells may replace a powerful anti-rejection drug in transplant recipients. The results of this pioneering study involving kidney transplant patients, published in the March 21 issue of the Journal of the American Medical Association, may fundamentally transform the future of clinical transplantation.

Researchers create neural stem cells from skin cells in 2 weeks: https://mdn.mainichi.jp/mdnnews/news/20120329p2a00m0na007000c.html . Japanese researchers have developed a method to create neural stem cells from human skin cells within two weeks. The technique is an improvement over the standard method used to create neural stem cells, which takes about six months. The findings were published in the journal Stem Cells.

AlloCure raises $25M for stem cell therapy:  AlloCure, developing a stem cell therapy dubbed AC607 for acute kidney disease, secured $25M in venture capital funding. The company will use the money to fund a multicenter, placebo-controlled trial of AC607, to begin this summer. The VC financing included new backer Lundbeckfrond Ventures, which joined existing investors SV Life Sciences.  

International Stem Cell Corporation Provides update on Lifeline Skin Care Business Activities: https://finance.yahoo.com/news/international-stem-cell-corporation-provides-120000306.html

 

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 56 minutes ago